IMTX Immatics N.V. IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1809196 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 183.83M | 148.08M | 118.66M | 106.78M | 87.57M |
| SG&A expense | 51.18M | 46.45M | 38.20M | 36.12M | 33.81M |
| Operating income | -182.02M | -38.62M | -101.72M | 29.95M | -86.29M |
| Interest expense | 946,000 | 886,000 | 831,000 | 1.04M | 566,000 |
| Pretax income | -198.44M | 21.35M | -96.99M | 42.04M | -93.33M |
| Income tax | -1.99M | 6.13M | -2.35M | 14.33M | 0 |
| Net income | -196.45M | 15.22M | -94.65M | 27.70M | -93.33M |
| EBITDA | -169.62M | -26.39M | -94.49M | 36.92M | -81.03M |
| EPS (basic) | -1.61 | 0.14 | -1.18 | 0.41 | -1.48 |
| EPS (diluted) | -1.61 | 0.14 | -1.18 | 0.40 | -1.48 |
| Weighted avg. shares (diluted) | 122.35M | 106.80M | 80.55M | 68.82M | 62.91M |
| Balance sheet | |||||
| Cash & equivalents | 345.92M | 236.75M | 218.47M | 148.52M | 132.99M |
| Receivables | 6.10M | 5.86M | 4.09M | 1.11M | 682,000 |
| Current assets | 504.01M | 629.55M | 449.37M | 377.15M | 152.21M |
| PP&E, netmay include right-of-use assets (IFRS) | 42.11M | 50.38M | 43.75M | 13.46M | 10.51M |
| Intangibles | 1.58M | 1.63M | 1.52M | 1.63M | 1.31M |
| Total assets | 562.34M | 696.15M | 509.96M | 407.82M | 174.65M |
| Current liabilities | 43.01M | 67.99M | 156.55M | 106.45M | 95.15M |
| Total liabilities | 78.24M | 121.30M | 292.35M | 204.47M | 150.58M |
| Shareholders' equity | 484.10M | 574.84M | 217.62M | 203.35M | 24.06M |
| Shares outstanding | — | — | — | — | 62.93M |
| Cash flow statement | |||||
| Operating cash flow | -176.63M | -158.03M | 18.23M | 100.13M | -84.75M |
| Capital expenditure | 6.56M | 16.27M | 30.80M | 5.74M | 5.11M |
| Free cash flow | -183.18M | -174.30M | -12.57M | 94.39M | -89.85M |
| Investing cash flow | 204.79M | -152.39M | -31.39M | -209.79M | 7.49M |
| Financing cash flow | 97.35M | 319.68M | 84.52M | 123.71M | -2.61M |
| Depreciation & amortization | 12.40M | 12.22M | 7.23M | 6.97M | 5.26M |
| Stock-based compensation | 15.02M | 17.64M | 20.70M | 22.57M | 26.40M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.